About us
Novaxelgen is a product-platform focused gene therapy company employing cutting-edge Adeno-Associated Virus (AAV) technology to novel cellular targets for treatment of cardiovascular diseases. Novaxelgen’s pioneer approach demonstrates dramatically therapeutic potency to treat heart failure, as such unlocking a full potential of targeted therapies against a broad array of cardiovascular diseases. At Novaxelgen, we approach our work as entrepreneurs and innovators, blazing trails that lead to better patient outcomes. We do so decisively and thoughtfully, drawing upon the decades of experience within our leadership team and advisory board. If you share our passion and sense of urgency for developing new medicines and are looking for a dynamic, collaborative and fulfilling work environment, we invite you to explore opportunities to join our team. Together, we are re-envisioning treatment of cardiovascular diseases.
- Industry
- Biotechnology Research
- Company size
- 11-50 employees
- Type
- Privately Held